Low-Dose Nivolumab Has Shown Promise for Hodgkin Lymphoma
Researchers presented findings on a cost-effective drug regimen for patients with Hodgkin lymphoma.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Do you trust that lower-cost medication options are just as effective as traditional high-cost treatments?
A phase 2 study presented at the SOHO 2026 Annual Meeting found that using low-dose nivolumab combined with AVD chemotherapy achieved a 95.8% response rate. The new regimen significantly reduced total drug costs while maintaining clinical efficacy in the 52 patients enrolled.
Why it matters
Reducing the required dosage of expensive immunotherapies could improve global access to essential treatments for lymphoma. Researchers are focused on whether this lower-dose approach maintains long-term safety and efficacy standards.
The study utilized a 40 mg dosage of nivolumab, achieving a 77.1% complete metabolic response rate after 2 cycles. Researchers noted that total drug costs were 75% lower compared to conventional nivolumab dosage.
The players
Society of Hematologic Oncology
This is an international organization that facilitates the exchange of research and best practices regarding blood cancers.
The details
In the study of 52 patients with a median age of 36, 92% completed at least two cycles of treatment. While overall response rates were high, adverse events included neutropenia in 46.7% of participants and transaminitis in 6.7%, with two patients discontinuing treatment due to immune toxicity.
Timeline
The research was presented between September 9 and September 12, 2026.
The Big Picture
This development aligns with the broader objective of the SOHO 2026 Annual Meeting to improve patient access through evidence-based dosage optimization. It reflects a growing trend in oncology to maintain therapeutic efficacy while reducing the significant economic burden of modern treatments.
If these results are validated in larger studies, patients could see lower financial barriers to accessing advanced immunotherapy treatments. However, patients should consult their medical teams about potential immune toxicity and side effects like neutropenia observed in this trial.
The takeaway
This study demonstrates that reduced dosages can provide substantial cost savings without compromising initial response rates. Patients and caregivers should continue to monitor clinical developments for updates on long-term safety and standard-of-care implementation.
What happens next
Further data will be released in the future as the study reaches its primary endpoint and matures beyond the current median follow-up of 11 months.
Further reading
For more information on similar developments, visit the Cancer section.
Live Poll
Do you trust that lower-cost medication options are just as effective as traditional high-cost treatments?
